US Stock MarketDetailed Quotes
ANIP ANI Pharmaceuticals
- 65.500
- +0.140+0.21%
Close Apr 29 16:00 ET
- 65.500
- 0.0000.00%
Post 16:20 ET
1.37BMarket Cap77.06P/E (TTM)
65.750High65.010Low75.52KVolume65.340Open65.360Pre Close4.94MTurnover0.47%Turnover Ratio77.06P/E (Static)20.98MShares70.81052wk High3.18P/B1.05BFloat Cap38.91052wk Low--Dividend TTM16.05MShs Float392.040Historical High--Div YieldTTM1.13%Amplitude4.800Historical Low65.440Avg Price1Lot Size
About ANI Pharmaceuticals Company
ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. It operates through the Generics, Established Brands, and Other, and Rare Disease segments. The Generics, Established Brands, and Other segment consists of contract manufactured products, development services, royalties, and other. The Rare Disease segment involves the operations related to Cortrophin Gel. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.
Company Profile
SymbolANIP
Company NameANI Pharmaceuticals
Listing DateOct 1, 2003
Founded1996
CEOMr. Nikhil Lalwani
MarketNASDAQ
Employees642
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address210 Main Street West
CityBaudette
ProvinceMinnesota
CountryUnited States of America
Zip Code56623
Phone1-218-634-3500
Company Executives
- Name
- Position
- Salary
- Nikhil Lalwani
- Director, President and Chief Executive Officer
- 8.08M
- Krista Davis
- Senior Vice President and Chief Human Resources Officer
- --
- Stephen P. Carey
- Senior Vice President, Finance, Principal Accounting Officer and Chief Financial Officer
- 2.58M
- Meredith W. Cook
- Senior Vice President, General Counsel and Corporate Secretary
- --
- Thomas Rowland
- Senior Vice President, Corporate Development & Strategy
- --
- Christopher Mutz
- Senior Vice President and Head of Rare Diseases
- 1.91M
- Chad Gassert
- Senior Vice President, Corporate Development and Strategy
- 1.90M
- Ori Gutwerg
- Senior Vice President, Generics
- 1.94M
- James G. Marken
- Senior Vice President, Operations and Product Development
- 1.87M
- Patrick D. Walsh
- Chairman of the Board
- 422.21K
- Matthew J. Leonard
- Director
- 928.31K
- Muthusamy Shanmugam
- Director, Head of Research and Development and Chief Operating Office, Novitium Operations
- --
- Thomas J. Haughey
- Independent Director
- 412.21K
- Antonio R. Pera
- Independent Director
- 393.25K
- Jeanne Thomas
- Independent Director
- 395.75K
- Dr. David B. Nash, M.B.A.,M.D.
- Independent Director
- 407.21K
- Dr. Renee P. Tannenbaum
- Independent Director
- 392.37K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg